Deletion of MTAP is frequently observed in a wide variety of cancers due to its proximity to the key tumour suppressor gene CDKN2A. The codeletion of MTAP provides a selectable marker for the identification of cancer patients who might benefit from targeting of methionine metabolism and/or protein methylation due to accumulation of the metabolite MTA. This evidence concerns the gene CDKN2A and cancer.